Soldatos G, Cooper M E
Vascular Divsion, Baker IDI Heart and Diabetes Institute, PO Box 6492, St. Kilda Road, Central Melbourne, Victoria 8008, Australia.
Diabetes Res Clin Pract. 2008 Nov 13;82 Suppl 1:S75-9. doi: 10.1016/j.diabres.2008.09.042.
With the global epidemic of type 2 diabetes mellitus, diabetes has become the leading cause of end stage renal failure (ESRF) in most Western countries. Approximately 20-30% of all diabetic subjects will develop evidence of diabetic nephropathy, which represents a continuum from microalbuminuria, to overt nephropathy or macroalbuminuria, and finally ESRF. While there have been significant breakthroughs in the last decade with regards to the prevention and treatment of diabetic kidney disease, in particular blockade of the renin angiotensin system, there is a vital need to identify and target novel pathophysiologic pathways such as advanced glycation which appear to be centrally involved in diabetic renal disease in order to reduce the rising burden of this disease.
随着2型糖尿病在全球范围内的流行，糖尿病已成为大多数西方国家终末期肾衰竭（ESRF）的主要原因。在所有糖尿病患者中，约20%-30%会出现糖尿病肾病的迹象，其表现为一个连续过程，从微量白蛋白尿到显性肾病或大量白蛋白尿，最终发展为ESRF。尽管在过去十年中，糖尿病肾病的预防和治疗取得了重大突破，尤其是肾素血管紧张素系统的阻断，但迫切需要识别并针对新的病理生理途径，如晚期糖基化，其似乎在糖尿病肾病中起核心作用，以减轻这种疾病日益加重的负担。
